- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Lilly likens relentless work of scientific and athletic progress in Winter Olympics ad | ||
| Fr | Roche's Genentech cut at least 489 jobs last year, new disclosure reveals | ||
| Fr | Biogen pins SMA recovery on high-dose Spinraza amid projected 2026 revenue slump | ||
| Fr | BridgeBio shares slide amid report that Pfizer will withdraw Vyndamax EU patent | ||
| Fr | FDA's Makary pledges crackdown on mass marketing of 'illegal copycat drugs' in wake of Hims' Wegovy pill push | ||
| Do | Community oncology's growing role in the future of cancer care | ||
| Do | TrumpRx, US government's cash-pay drug purchasing portal, primed for launch | ||
| Do | Him & Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action | ||
| Do | With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm | ||
| Do | Astellas tops expectations as Vyloy sales surge outshines trial setback | ||
| Do | A cut above: Veradermics locks in $256M IPO and shares spike | ||
| Do | Merz steps into the ring with Muhammad Ali-inspired Inbrija campaign | ||
| Mi | FDA's rare pediatric disease voucher program revived by 2026 government funding bill | ||
| Mi | Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026 | ||
| Mi | AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&J competition | ||
| Mi | Novartis CEO projects 2026 growth despite 'largest patent expiry' in company history | ||
| Mi | BMS celebrates US soccer legend's shutout against cancer in Breyanzi collab | ||
| Mi | OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts | ||
| Mi | As CEO, Luke Miels wants GSK to be more 'product-centric' | ||
| Mi | Amgen resists FDA request to pull rare disease drug Tavneos from the market | ||
| Di | India will invest $1.1B to boost development of biologics, biosimilars | ||
| Di | Novo shares plummet on sales, profit warning for '26 as 2 top execs head for the doors | ||
| Di | Charles River to close cell therapy CDMO site, lay off 20 staffers | ||
| Di | Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade | ||
| Di | FDA signals tailored approach to 'carefully shepherd' CAR-T therapy for autoimmune diseases |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.